From August 29 to September 1, 2020, the annual congress of the European Society of Cardiology (ESC), the world’s largest cardiovascular congress, will take place, and for the first time in a virtual setting.

Cardiovascular disease remains the leading cause of death in the world today. Worldwide, more than 17 million people die from cardiovascular disease each year, representing 31% of total global mortality*. And more than 108 million people were living with cardiovascular disease in the 54 ESC member countries in 2017**.

Focused on the prevention and treatment of cardiovascular risks and diseases, the ESC brings together cardiologists, physicians, researchers, caregivers, healthcare manufacturers and other scientific experts from around the world to review and share news in this therapeutic field.

The Servier Group has been a major partner of the ESC for several years and will continue to be one of the main pharmaceutical companies present at this digital congress. As a result, WeHealth™ Digital Medicine, Servier’s e-health division, will have a dedicated space on the Group’s 3D booth. In an open innovation approach, WeHealth™ Digital Medicine identifies the most promising startups to co-construct innovative and connected solutions.

The ESC program includes six Q&A sessions organized by Medical Affairs and WeHealth™ Digital Medicine.

As a result, we are introducing digital solutions:

SATELIA® CARDIO ***: a web application which allows the remote monitoring and therapeutic support of patients suffering from chronic heart failure. It is co-developed with the start-up NP Medical.

ESC congress website

Source: * World Health Organization (WHO), 2019. **European Society of Cardiology: Statistics 2019

*** In France, Servier Laboratories, WeHealth™ Digital Medicine located at 50 rue Carnot, 92284 Suresnes cedex distributes Satelia® Cardio only in the French overseas territories. Outside of both France and the French overseas territories, the solution is known as Heartkeeper™.